SecBot SecBot
Biotech Drug Report Generated Nov 11, 2026

ZYNLONTA

ADCT·ADC Therapeutics SA
MIXED
Drug Impact Rating4/10
Trial phase
Approved (accelerated approval); Phase 3 confirmatory (LOTIS-5) completed; Phase 1b combination (LOTIS-7) ongoing
Time to market
Already on the market (FDA accelerated approval April 2021). Path to full FDA approval is uncertain after LOTIS-5 safety issues. Japan decision timeline is not specified.
Why 4/10
ZYNLONTA is already approved and generating commercial revenue, so there is no pending PDUFA or pivotal readout that represents a single binary event for the stock. The next hard catalyst is the ASH 2026 data presentations (December 5-8, 2026), but these are data updates, not a regulatory decision. The Japan filing decision and the FDA path to full approval are important but lack dated timelines. Per the impact score rubric, an approved drug with no imminent new regulatory decision scores 3-5; this is set at 4 reflecting that ZYNLONTA is the company's only product and drives the entire thesis, but no binary catalyst is scheduled within 6 months.
Actionable Insight MIXED

Watch the 68th ASH Annual Meeting (December 5-8, 2026) where multiple ZYNLONTA abstracts will be presented, including updated LOTIS-7 combination data and potentially the full LOTIS-5 dataset. Also monitor the Japan marketing authorization decision by Tanabe Pharma (filed October 29, 2026) and any FDA guidance on the path to full approval. The stock trades near $1.51 with a 52-week range of $0.78-$4.98, reflecting deep uncertainty around the regulatory path.

Price Chart

Loading chart...

Executive Summary

ZYNLONTA (loncastuximab tesirine-lpyl) is a CD19-directed antibody-drug conjugate that received FDA accelerated approval in 2021 for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of therapy. It is the only marketed product of ADC Therapeutics (NYSE: ADCT), a commercial-stage Swiss biotech. The drug generated $21M in Q3 2026 net product revenue (up 33% YoY), the fourth straight quarterly beat. However, the confirmatory Phase 3 LOTIS-5 trial (ZYNLONTA + rituximab) posted a 13% death rate in June 2026, sending shares down ~50% and prompting the FDA to cite significant safety concerns. The company is now evaluating an alternative regulatory path for full approval while advancing earlier-line combination studies (LOTIS-7 with bispecific antibodies). A financial restructuring in October 2026, including an $86.6M PIPE, extended the cash runway into 2029.

How It Works

ZYNLONTA is an antibody-drug conjugate (ADC) that works like a guided missile. The antibody portion targets CD19, a protein found on the surface of B-cell lymphoma cells. Once bound, the drug releases a toxic payload (a pyrrolobenzodiazepine dimer) that kills the cancer cell. It is given as an intravenous infusion.

Trial Status

ZYNLONTA is FDA-approved under accelerated approval for third-line+ relapsed/refractory DLBCL. The confirmatory Phase 3 LOTIS-5 trial (ZYNLONTA + rituximab vs. standard chemo) reported topline data in June 2026 showing elevated deaths (13% in the study arm), leading the FDA to cite significant concerns. The company is evaluating an alternative regulatory path. LOTIS-7 (Phase 1b, ZYNLONTA + bispecific antibody mosunetuzumab) completed enrollment in June 2026 with encouraging initial safety data. Multiple abstracts accepted for the 68th ASH Annual Meeting in December 2026. A Japan marketing authorization application was filed by partner Tanabe Pharma in October 2026.

The Two-Sided Case

▲ Bull Case5
ZYNLONTA product revenue grew 33% YoY to $21M in Q3 2026, the fourth straight quarter ahead of consensus, showing commercial traction in its approved indication
Cash runway extended into 2029 after an $86.6M PIPE from healthcare-focused investors (Redmile, TCG Crossover, Bain Capital Life Sciences) and debt refinancing, removing near-term financing risk
LOTIS-7 (ZYNLONTA + bispecific antibody) showed no dose-limiting toxicities or high-grade CRS/ICANS in initial data, suggesting a potentially safer combination path
Japan filing by Tanabe Pharma (October 2026) opens a new geographic market; Nippon Shinyaku sublicensed Japanese rights, adding a commercial partner
Analyst consensus shows 4 Buy/Strong Buy vs. 1 Strong Sell, with a mean price target of $3.33 (120% upside from $1.51)
▼ Bear Case5
LOTIS-5 confirmatory trial showed a 13% death rate in the ZYNLONTA + rituximab arm, causing shares to drop ~50% and the FDA to cite 'significant concerns' about the combination regimen
The path to full FDA approval is now uncertain; the company is evaluating alternatives after the pre-sBLA meeting, and the accelerated approval could be at risk if a confirmatory path is not agreed upon
Competition in DLBCL is intense: CAR-T therapies (Yescarta, Breyanzi), bispecific antibodies (Glofitamab, Epcoritamab), and other ADCs all target the same patient population
Stock trades at $1.51 with a 52-week range of $0.78-$4.98; quant composite score is -57 (negative momentum/value/volatility profile) and the stock is down 63% over 12 months
RBC Capital Markets downgraded the stock after LOTIS-5 data, and revenue growth outlook remains unclear per analyst commentary

Upcoming Catalysts

  • 68th ASH Annual Meeting (December 5-8, 2026): Multiple ZYNLONTA abstracts including LOTIS-7 combination data and potentially full LOTIS-5 results
  • Japan marketing authorization decision by Ministry of Health, Labor and Welfare (filed October 29, 2026 by partner Tanabe Pharma)
  • FDA regulatory path update: Company evaluating alternative path to full approval after pre-sBLA meeting

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ADC Therapeutics SA S-3 ADCT ·Originating report

Sources · 10

Hover a chip for the title
1 prnewswire.com2 rttnews.com3 fiercepharma.com4 pharmaphorum.com5 aol.com6 rttnews.com7 biospace.com8 morningstar.com9 247wallst.com10 prnewswire.com